Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic bax

Marissa V. Powers, Melanie Valenti, Susana Miranda, Alison Maloney, Suzanne A. Eccles, George Thomas, Paul A. Clarke, Paul Workman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Inhibitors of the molecular chaperone heat shock protein 90 (HSP90) are of considerable current interest as targeted cancer therapeutic agents because of the ability to destabilize multiple oncogenic client proteins. Despite their resulting pleiotropic effects on multiple oncogenic pathways and hallmark traits of cancer, resistance to HSP90 inhibitors is possible and their ability to induce apoptosis is less than might be expected. Using an isogenic model for BAX knockout in HCT116 human colon carcinoma cells, we demonstrate the induction of BAX-dependent apoptosis at pharmacologically relevant concentrations of the HSP90 inhibitor 17-AAG both in vitro and in tumor xenografts in vivo. Removal of BAX expression by homologous recombination reduces apoptosis in vitro and in vivo but allows a lower level of cell death via a predominantly necrotic mechanism. Despite reducing apoptosis, the loss of BAX does not alter the overall sensitivity to 17-AAG in vitro or in vivo. The results indicate that 17-AAG acts predominantly to cause a cytostatic antiproliferative effect rather than cell death and further suggest that BAX status may not alter the overall clinical response to HSP90 inhibitors. Other agents may be required in combination to enhance tumor-selective killing by these promising drugs. In addition, there are implications for the use of apoptotic endpoints in the assessment of the activity of molecularly targeted agents.

Original languageEnglish (US)
Pages (from-to)1963-1975
Number of pages13
JournalOncotarget
Volume4
Issue number11
StatePublished - Nov 2013

Fingerprint

tanespimycin
HSP90 Heat-Shock Proteins
Cell Death
Apoptosis
Neoplasms
Molecular Chaperones
Homologous Recombination
Cytostatic Agents
Heterografts
Colon
Carcinoma
Pharmaceutical Preparations
In Vitro Techniques

Keywords

  • 17-AAG
  • Apoptosis
  • BAX
  • Colon cancer
  • HSP90

ASJC Scopus subject areas

  • Oncology

Cite this

Powers, M. V., Valenti, M., Miranda, S., Maloney, A., Eccles, S. A., Thomas, G., ... Workman, P. (2013). Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic bax. Oncotarget, 4(11), 1963-1975.

Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic bax. / Powers, Marissa V.; Valenti, Melanie; Miranda, Susana; Maloney, Alison; Eccles, Suzanne A.; Thomas, George; Clarke, Paul A.; Workman, Paul.

In: Oncotarget, Vol. 4, No. 11, 11.2013, p. 1963-1975.

Research output: Contribution to journalArticle

Powers, MV, Valenti, M, Miranda, S, Maloney, A, Eccles, SA, Thomas, G, Clarke, PA & Workman, P 2013, 'Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic bax', Oncotarget, vol. 4, no. 11, pp. 1963-1975.
Powers, Marissa V. ; Valenti, Melanie ; Miranda, Susana ; Maloney, Alison ; Eccles, Suzanne A. ; Thomas, George ; Clarke, Paul A. ; Workman, Paul. / Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic bax. In: Oncotarget. 2013 ; Vol. 4, No. 11. pp. 1963-1975.
@article{71f95a021f03418183b35c583e4d1fae,
title = "Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic bax",
abstract = "Inhibitors of the molecular chaperone heat shock protein 90 (HSP90) are of considerable current interest as targeted cancer therapeutic agents because of the ability to destabilize multiple oncogenic client proteins. Despite their resulting pleiotropic effects on multiple oncogenic pathways and hallmark traits of cancer, resistance to HSP90 inhibitors is possible and their ability to induce apoptosis is less than might be expected. Using an isogenic model for BAX knockout in HCT116 human colon carcinoma cells, we demonstrate the induction of BAX-dependent apoptosis at pharmacologically relevant concentrations of the HSP90 inhibitor 17-AAG both in vitro and in tumor xenografts in vivo. Removal of BAX expression by homologous recombination reduces apoptosis in vitro and in vivo but allows a lower level of cell death via a predominantly necrotic mechanism. Despite reducing apoptosis, the loss of BAX does not alter the overall sensitivity to 17-AAG in vitro or in vivo. The results indicate that 17-AAG acts predominantly to cause a cytostatic antiproliferative effect rather than cell death and further suggest that BAX status may not alter the overall clinical response to HSP90 inhibitors. Other agents may be required in combination to enhance tumor-selective killing by these promising drugs. In addition, there are implications for the use of apoptotic endpoints in the assessment of the activity of molecularly targeted agents.",
keywords = "17-AAG, Apoptosis, BAX, Colon cancer, HSP90",
author = "Powers, {Marissa V.} and Melanie Valenti and Susana Miranda and Alison Maloney and Eccles, {Suzanne A.} and George Thomas and Clarke, {Paul A.} and Paul Workman",
year = "2013",
month = "11",
language = "English (US)",
volume = "4",
pages = "1963--1975",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

TY - JOUR

T1 - Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic bax

AU - Powers, Marissa V.

AU - Valenti, Melanie

AU - Miranda, Susana

AU - Maloney, Alison

AU - Eccles, Suzanne A.

AU - Thomas, George

AU - Clarke, Paul A.

AU - Workman, Paul

PY - 2013/11

Y1 - 2013/11

N2 - Inhibitors of the molecular chaperone heat shock protein 90 (HSP90) are of considerable current interest as targeted cancer therapeutic agents because of the ability to destabilize multiple oncogenic client proteins. Despite their resulting pleiotropic effects on multiple oncogenic pathways and hallmark traits of cancer, resistance to HSP90 inhibitors is possible and their ability to induce apoptosis is less than might be expected. Using an isogenic model for BAX knockout in HCT116 human colon carcinoma cells, we demonstrate the induction of BAX-dependent apoptosis at pharmacologically relevant concentrations of the HSP90 inhibitor 17-AAG both in vitro and in tumor xenografts in vivo. Removal of BAX expression by homologous recombination reduces apoptosis in vitro and in vivo but allows a lower level of cell death via a predominantly necrotic mechanism. Despite reducing apoptosis, the loss of BAX does not alter the overall sensitivity to 17-AAG in vitro or in vivo. The results indicate that 17-AAG acts predominantly to cause a cytostatic antiproliferative effect rather than cell death and further suggest that BAX status may not alter the overall clinical response to HSP90 inhibitors. Other agents may be required in combination to enhance tumor-selective killing by these promising drugs. In addition, there are implications for the use of apoptotic endpoints in the assessment of the activity of molecularly targeted agents.

AB - Inhibitors of the molecular chaperone heat shock protein 90 (HSP90) are of considerable current interest as targeted cancer therapeutic agents because of the ability to destabilize multiple oncogenic client proteins. Despite their resulting pleiotropic effects on multiple oncogenic pathways and hallmark traits of cancer, resistance to HSP90 inhibitors is possible and their ability to induce apoptosis is less than might be expected. Using an isogenic model for BAX knockout in HCT116 human colon carcinoma cells, we demonstrate the induction of BAX-dependent apoptosis at pharmacologically relevant concentrations of the HSP90 inhibitor 17-AAG both in vitro and in tumor xenografts in vivo. Removal of BAX expression by homologous recombination reduces apoptosis in vitro and in vivo but allows a lower level of cell death via a predominantly necrotic mechanism. Despite reducing apoptosis, the loss of BAX does not alter the overall sensitivity to 17-AAG in vitro or in vivo. The results indicate that 17-AAG acts predominantly to cause a cytostatic antiproliferative effect rather than cell death and further suggest that BAX status may not alter the overall clinical response to HSP90 inhibitors. Other agents may be required in combination to enhance tumor-selective killing by these promising drugs. In addition, there are implications for the use of apoptotic endpoints in the assessment of the activity of molecularly targeted agents.

KW - 17-AAG

KW - Apoptosis

KW - BAX

KW - Colon cancer

KW - HSP90

UR - http://www.scopus.com/inward/record.url?scp=84890215177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890215177&partnerID=8YFLogxK

M3 - Article

C2 - 24185264

AN - SCOPUS:84890215177

VL - 4

SP - 1963

EP - 1975

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -